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Relationship of Metabolic Syndrome With Incident Aortic
Valve Calcium and Aortic Valve Calcium Progression
The Multi-Ethnic Study of Atherosclerosis (MESA)*
Ronit Katz,1 Matthew J. Budoff,2 Junichiro Takasu,2 David M. Shavelle,2 Alain Bertoni,3
Roger S. Blumenthal,4 Pamela Ouyang,4 Nathan D. Wong,5 and Kevin D. O’Brien1
OBJECTIVE—Metabolic syndrome (MetS) has been associated
with increased prevalence of aortic valve calcium (AVC) and
with increased progression of aortic stenosis. The purpose of this
study was to determine whether MetS is associated with in-
creased risks for the development of new (“incident”) AVC or for
progression of established AVC as assessed by CT.
RESEARCH DESIGN AND METHODS—The relationships of
MetS or its components as well as of diabetes to risks for
incident AVC or AVC progression were studied among partici-
pants with CT scans performed at baseline and at either year 2 or
year 3 examinations in the Multi-Ethnic Study of Atherosclerosis
(MESA).
RESULTS—Of 5,723 MESA participants meeting criteria for
inclusion, 1,674 had MetS by Adult Treatment Panel III criteria,
whereas 761 had diabetes. Among the 5,123 participants without
baseline AVC, risks for incident AVC, adjusted for time between
scans, age, sex, race/ethnicity, LDL cholesterol, lipid-lowering
medications, and smoking, were increased significantly for MetS
(odds ratio [OR] 1.67 [95% CI 1.21–2.31]) or diabetes (2.06
[1.39–3.06]). In addition, there was an increase in incident AVC
risk with increasing number of MetS components. Similar results
were found using the International Diabetes Federation MetS
criteria. Among the 600 participants (10.5%) with baseline AVC,
neither MetS nor diabetes was associated with AVC progression.
CONCLUSIONS—In the MESA cohort, MetS was associated
with a significant increase in incident (“new”) AVC, raising the
possibility that MetS may be a potential therapeutic target to
prevent AVC development. Diabetes 58:813–819, 2009
Metabolic syndrome (MetS) is a collection ofclinical and laboratory abnormalities com-prised of central adiposity, hypertriglyceride-mia, low HDL cholesterol, elevated blood
pressure, and/or impaired fasting glucose (1,2). Overall
MetS prevalence has been estimated at 25% in Western
populations (2,3) but is almost certainly increasing as a
consequence of the worldwide epidemic of obesity (4,5).
MetS is associated with both increased prevalence of
coronary atherosclerosis (1,2,6,7) and increased risk for
clinical cardiovascular events (8,9).
Cross-sectional U.S. data show that the prevalence of
MetS increases with age (3), suggesting that MetS might
contribute to risk for diseases with increased prevalence
in the elderly. Examples of these diseases include both
atherosclerosis (10) and calcific aortic valve disease
(CAVD), which has a prevalence of 25% in those older than
age 65 years (11). CAVD is comprised of aortic sclerosis, in
which the valve is calcified and thickened but does not
obstruct left ventricular outflow, and aortic stenosis, in
which obstruction to left ventricular outflow is present
(12,13). Aortic sclerosis is associated with an 50% in-
crease in cardiovascular events (14), and aortic stenosis is
associated with a 5-year risk of 80% risk for valve replace-
ment surgery or clinical cardiovascular events (15).
Previous studies have shown that the MetS and diabetes
are associated with the presence of coronary artery cal-
cium as assessed by cardiac CT (7). In the Multi-Ethnic
Study of Atherosclerosis (MESA) cohort, in which the
overall MetS prevalence by Adult Treatment Panel (ATP)
III criteria is 21%, not only is MetS associated with
increased prevalence of CT-detected aortic valve calcium
(AVC), but also increased number of MetS features is
associated with increased AVC prevalence (16). Metabolic
syndrome also has been associated with increased pro-
gression of aortic stenosis (17) and accelerated degenera-
tion of bioprosthetic aortic valves (18).
It is not known, however, whether abnormalities in
glucose metabolism/insulin resistance, as typified by the
clinical syndromes of MetS and diabetes, are associated
with increased likelihood of incident (“new”) AVC or AVC
progression. We sought to evaluate potential associations
of the MetS and diabetes both in the development of
incident AVC as well as in the progression of established
AVC using data from a multi-ethnic cohort of men and
women, MESA.
RESEARCH DESIGN AND METHODS
Study population. The MESA cohort consists of 6,814 men and women, aged
45 to 84 years, recruited from six U.S. communities (Baltimore, MD; Chicago,
IL; Forsyth County, NC; Los Angeles County, CA; northern Manhattan, NY; and
St. Paul, MN) and who were free of clinically evident cardiovascular disease
at the time of enrollment (baseline). The main objective of MESA is to
determine the characteristics of subclinical cardiovascular disease and its
progression. Participants were excluded if they had a history of any of the
following procedures: coronary bypass surgery, balloon angioplasty, heart
valve replacement, pacemaker or defibrillator implantation, or history of any
other cardiac surgery. The study was designed to include the following
self-identified ethnic groups: whites, African Americans, Hispanics, and Chi-
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nese Americans. Sampling and recruitment procedures have been previously
described in detail (19). Participants were enrolled between 1 August 2000,
and 30 July 2002. The institutional review boards at all participating centers
approved the study, and all participants gave informed consent.
Questionnaires were used to obtain information about socioeconomic
status, medical history, medication, and tobacco use. Smoking was defined as
current, former, or never. Waist circumference at the umbilicus was measured
to the nearest 0.1 cm using a steel measuring tape (standard 4-ounce tension).
Resting blood pressure was measured three times with participants in the
seated position with a Dinamap model Pro 100 automated oscillometric
sphygmomanometer (Critikon). The average of the last two measurements
was used in this analysis. Total and HDL cholesterol, triglycerides, and
glucose levels were measured from blood samples obtained after a 12-h fast.
LDL cholesterol was calculated with the Friedewald equation (20).
Diabetes and metabolic syndrome. Participants were considered to have
diabetes if they met the following criteria: self-reported history of adult onset
of diabetes, fasting glucose 126 mg/dl or greater, or use of insulin or oral
glucose-lowering medications.
Among those without diabetes, MetS was defined using ATP III (21)–
modified criteria. These criteria require three or more of the following five
criteria for MetS diagnosis: large waist circumference (women 88 and men
102 cm); elevated triglycerides (150 mg/dl); low HDL cholesterol (men
40 and women 50 mg/dl); elevated blood pressure (130/85 mmHg or
self-reported use of medications for hypertension); and impaired fasting
glucose (100–125 mg/dl) as defined in the updated American Heart Associa-
tion/National Heart, Lung, and Blood Institute guidelines (1). Results also
were analyzed using the International Diabetes Federation (IDF) definition of
MetS.
Measurement of aortic valve calcium by CT. AVC was measured using
either electron-beam tomography (three sites) or multidetector CT (three
sites). A total calcium score was determined by summing individual lesion
scores at each anatomic site. Any calcified focus seen extending to the aortic
root was deemed AVC by methodology described previously (22–24). Calcifi-
cation involving either the aortic or mitral annuli was not included. AVC score
was assessed in every patient. The calcium score of each lesion was calculated
by multiplying the lesion area by a density factor derived from the maximal
Hounsfield units within this area as described by Agatston (25). The absence
of AVC was deemed a score of 0. Details of the scanning methodology used for
AVC in the MESA study have been reported (23), and the median interscan
variability for Agatston AVC scores within the MESA cohort is 6.4% (23). All
studies were analyzed at the MESA CT reading center at Harbor-UCLA.
To define AVC progression, a second AVC measurement was performed on
a random selection of half the cohort at exam 2 (September 2002 to January
2004) and on the other half of the cohort at exam 3 (March 2004 to July 2005).
The mean time between scans was 2.4 (0.9) years.
Data analyses. The study population for this analysis includes all MESA
participants who had no missing data on any component of MetS with both
baseline (exam 1) and follow-up (exam 2 or 3) CT scans. After applying these
criteria, 5,723 individuals remained for analysis.
Participants were classified by the presence or absence of the MetS and
diabetes, creating three groups (diabetes, MetS, and neither condition).
Baseline demographics and laboratory measures were expressed with means
and proportions and compared across groups using the 2 test and ANOVA.
Because the exact date of development of incident AVC is not known, risk
time was calculated as the elapsed time from the baseline to the second or
third MESA examination. Unadjusted incident AVC rates were calculated as
the number of events divided by person-years at risk, and incident AVC rates
were examined according to the three groups of neither condition, MetS, or
diabetes.
Two end points were created and modeled separately. The primary
outcome of interest was incident progression of AVC defined as detectable
AVC (AVC score 0) at follow-up (either exam 2 or 3) among those with no
AVC (AVC  0) at the baseline examination. This was treated as a dichoto-
mous end point, and yearly incidence rates were calculated among the three
groups. Logistic regression was used to evaluate the association between
incident AVC and the MetS and diabetes groups. Unadjusted analyses were
performed followed by multivariable modeling that included age, ethnicity,
and time between scans. A second adjusted model added LDL cholesterol,
lipid-lowering medication use, smoking status, and scanner type (to account
for scanner changes that were made at some of the sites).
A secondary outcome looked at AVC progression defined as an absolute
change in AVC score among those with detectable AVC at exam 1. The
absolute change was calculated as the difference between AVC score at
follow-up and baseline. This was treated as a continuous end point for which
we found that 62 participants (10.3%) had very large residuals and therefore
used robust linear regression to downweight their influence (26,27). The same
modeling strategy used for incident AVC, as described, was used for AVC
progression with additional adjustment for baseline AVC score.
We also looked at the number of MetS risk factors while treating diabetes
as a separate category in order to explore relative associations of individual
MetS components and of the number of components with incidence and
progression of AVC using those with 0 MetS risk factors as the reference
group. Because the numbers of participants who had four or five risk factors
were relatively small, they were grouped together.
Interactions were evaluated between the three groups and each sex as well
as between the three groups and each race. A P value 0.05 was considered
statistically significant. Statistical analyses were performed with S-Plus (re-
lease 6.1; Insightful, Seattle, WA) and SPSS 15.0.1 software for Windows
(SPSS, Chicago, IL).
RESULTS
Participant characteristics. The study population for
these analyses included 5,723 MESA subjects with a mean
age of 62 years (SD  10); 52% were female, 27% were
African American, 12% were Chinese, and 22% were His-
panic. Of these, 1,674 (29%) met the ATP III definition for
MetS and an additional 761 (13%) met the definition for
diabetes. Table 1 shows the distribution of demographics
and components of the MetS by MetS and diabetes groups.
Participants with neither MetS nor diabetes were more
likely to be younger; have lower values for BMI, triglycer-
ides, and systolic blood pressure; and higher values for
HDL. Large waist circumference was the most common
component for the MetS (83%), whereas high blood pres-
sure was the most common component for diabetes (77%).
Of the 5,123 participants with an AVC of 0 at baseline,
211 (4%) developed an AVC greater than 0 over follow-up
(new “incident” AVC). The breakdown by condition is 88
(3%) for neither MetS nor diabetes, 79 (5%) for MetS, and
44 (7%) for diabetes (P  0.0001). At baseline, there were
600 (11%) participants with AVC greater than 0 who were,
therefore, classified as at risk for AVC progression. Of
these, 266 (8%) had neither MetS nor diabetes, 204 (12%)
had MetS only, and 130 (17%) had diabetes (P  0.001).
The median baseline AVC score for these 600 participants
was 68 Agatston units (interquartile range [IQR] 25–152).
The median (IQR) baseline AVC scores were, by condition,
54 (22–144) for neither MetS nor diabetes, 80 (25–178) for
MetS, and 63 (27–113) for diabetes (P  0.335).
Incident AVC
Rates for incident AVC by metabolic syndrome,
diabetes, or neither condition. Incident (“new”) AVC
was higher among those with either MetS or diabetes as
compared with those with neither condition. The yearly
rate of incident AVC per 100 person-years (among partic-
ipants without AVC at baseline) in subjects with the MetS
was lower than in those with diabetes (Fig. 1, left). Rates
of incident AVC were 2.2% per year in those with ATP
III–defined MetS and 3.0% per year in those with diabetes
as compared with 1.2% per year in those with neither (P 
0.0001 for ATP III MetS versus neither condition and P 
0.0001 for diabetes versus neither condition). Similar
results were obtained using the IDF criteria for MetS (Fig.
1, right). There was no sex or race interaction for the
relationship of either MetS or diabetes with incident AVC
(P for interaction  0.633 and 0.581, respectively).
Rates of incident AVC by number of MetS components.
There was a graded, linear association between the rate
of incident AVC and the number of MetS components.
Those with diabetes had the highest rates of incident
AVC (Fig. 2).
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Multivariable analyses: odds ratios for incident
AVC. In logistic regression analyses adjusted for age, sex,
ethnicity, and time between scans, the odds ratios (ORs)
for incident AVC were significantly higher in participants
with either the MetS (1.73 [95% CI 1.25–2.38]) or diabetes
(2.16 [1.46–3.19]) as compared with those with neither
condition. These associations persisted after additional
adjustment for LDL cholesterol, lipid-lowering medication
use, and smoking (MetS, OR 1.67 [1.21–2.31], and diabetes,
2.06 [1.39–3.06]) (Table 2).
Risks for incident AVC by number of MetS components.
When examining the ORs for incident AVC by number of
MetS components (Fig. 3), a similar pattern emerged. As
compared with those with no MetS components, partici-
pants with three MetS risk factors, four to five MetS risk
factors, and diabetes had a significantly increased risk of
incident AVC in a model adjusted for age, sex, ethnicity,
time between scans, LDL cholesterol, use of lipid-lowering
medication, and smoking (OR, 1.88 [95% CI 1.01–3.51], 2.24
[1.16–4.30], and 2.50 [1.32–4.73], respectively).
Incident AVC and individual MetS components. We
evaluated the association of individual components of the
MetS with incident AVC (Table 3) in those participants
without diabetes. Each of the five MetS components was
added in the model simultaneously, and the model was
then further adjusted for age, sex, ethnicity, time between
scans, LDL cholesterol, lipid-lowering medication, and
smoking. Incident AVC was only related to low HDL
(adjusted OR 1.54 [95% CI 1.08–2.19]). In both unadjusted
and demographic-adjusted analyses, there were associa-
tions between impaired fasting glucose and incident AVC,
but these associations were attenuated and of marginal
statistical significance after multivariable adjustment (1.36
[0.97–1.90]).
Given the strong relationship of AVC among those with
diabetes, we also looked at the association of continuous
glucose (per 10 mg/dl). For participants without diabetes,
the unadjusted model showed a strong increased risk
between glucose and incident AVC (OR 1.33 [95% CI
1.14–1.55]). Although this risk was attenuated after full
adjustment, it remained significantly elevated (1.18 [1.01–
1.40]).
AVC progression. Among those with AVC at baseline
(n  600), the median (IQR) annualized rate of AVC score
change was 5.4 (2.0 to 23.0) Agatston units per year. The
rate of AVC score change did not vary significantly by
MetS or diabetes status (P 0.341 by Kruskal-Wallis) (Fig.
4). When examining the median AVC change by number of
TABLE 1
Characteristics of participants with diabetes, ATP III–defined MetS, or neither condition
Neither
condition MetS Diabetes P
n 3,288 1,674 761
Age (years) 61 10 63  10 65  9 0.001
Men 1,601 (49) 716 (43) 406 (53) 0.001
Race/ethnicity 0.001
Caucasian 1,440 (44) 677 (40) 151 (20)
Chinese American 428 (13) 151 (9) 95 (13)
African American 823 (25) 435 (26) 285 (38)
Hispanic 597 (18) 411 (25) 230 (30)
Glucose (mg/dl) 93 9 101  10 155 53 0.001
BMI (kg/m2) 26.5 4.7 30.9 5.2 30.6 5.7 0.001
Total cholesterol (mg/dl) 194 33 196 36 189 39 0.001
HDL cholesterol (mg/dl) 56 15 44  11 46  12 0.001
LDL cholesterol (mg/dl) 118 30 117 31 112 33 0.111
Triglycerides (mg/dl) 93 (68–124) 162 (112–210) 134 (87–199) 0.001
Lipid-lowering medications 393 (12) 326 (20) 206 (27) 0.001
Diastolic blood pressure (mmHg) 71 10 74  10 72  10 0.001
Systolic blood pressure (mmHg) 121 20 133 21 132 21 0.001
Antihypertensive medications 714 (22) 821 (49) 465 (61) 0.001
Current smoker 405 (12) 229 (14) 91 (12) 0.556
Metabolic syndrome components*
Abdominal obesity (large waist) 1,140 (35) 1,393 (83) 518 (68) 0.001
High blood pressure 1,263 (38) 1,301 (78) 584 (77) 0.001
LDL cholesterol 547 (17) 1,119 (67) 385 (51) 0.001
High triglycerides 359 (11) 994 (59) 334 (44) 0.001
Impaired fasting glucose (100–125 mg/dl)† 568 (17) 1,013 (61) 0 (0) 0.001
Data are n (%), means  SD, or means (interquartile range). *At least three of the five following conditions define presence of MetS: high
blood pressure, low HDL cholesterol, high triglycerides, impaired fasting glucose, or large waist. †American Diabetes Association definition
of impaired fasting glucose.
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FIG. 1. Rates of incident AVC for diabetes (f), MetS (o), or neither
condition () using MetS criteria as defined by ATP III (left) or IDF
(right).
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MetS components, no pattern emerged (P  0.634 by
Kruskal-Wallis, results not shown). Adjusted robust re-
gression also showed that there was no significant AVC
progression in Agatston units per year for either the MetS
or diabetes compared with neither condition (results not
shown).
DISCUSSION
Only one prospective study has demonstrated an associa-
tion of MetS with increased risk for prevalent AVC (16),
whereas retrospective studies have demonstrated that
MetS is associated with increased rates of aortic stenosis
progression (17) and bioprosthetic valve deterioration
(18). AVC incidence is more important than prevalent AVC
because it provides stronger evidence in establishing
causality. By separating predictor and outcome variable
over time, the longitudinal analysis reduces systematic
bias and enhances causal inference. The present study is
the first to prospectively examine the relationship of MetS
to risks for incident (“new”) AVC and AVC progression. In
fully adjusted analyses, both MetS and the number of MetS
components were associated strongly with increased risk
for incident AVC. We did not, however, identify an asso-
ciation of either MetS or diabetes with the rate of AVC
progression.
The relationship of advanced dysglycemia, that is, clin-
ical diabetes, to aortic valve disease pathology has been
demonstrated in previous small, retrospective studies re-
porting associations of diabetes with increased prevalence
of AVC (28) as well as with increased prevalence (29) and
progression (30) of aortic stenosis. We and others have
extended the relationship of less severe dysglycemia, that
is, MetS, to aortic valve disease pathology by demonstrat-
ing that MetS is associated not only with increased prev-
alence of AVC (16), but also with faster aortic stenosis
progression (17) and more rapid deterioration of biopros-
thetic aortic valves (18). The results of the present study
further extend the relationship of MetS to early-stage
aortic valve disease pathology by demonstrating that MetS
and MetS components are associated with an increased
rate of new (“incident”) AVC. In our study, participants
with diabetes and the MetS had the highest prevalence of
new (“incident”) AVC.
The association of the dysglycemias, including diabetes
and MetS, with increased risks for prevalent vascular (6,7)
and valvular (16) calcification has been established, and
interesting studies have begun to elucidate potential mech-
anisms that may underlie these associations. The key
osteogenic regulatory factor, bone morphogenic protein
(BMP)2, is upregulated by hyperglycemia in vitro. (31,32)
BMP2 has been demonstrated to play a role in vascular
calcification (33,34) and has been detected in areas of
valvular calcification (35). BMP2 upregulates both “osteo-
genic” differentiation regulated by the transcription factor
Msx2 and “chondro-ostegenic” differentiation regulated by
the transcription factor Runx2/Cbfa1 (36).
Diabetes is characterized by a pro-oxidant state (37,38).
Not only are oxidized lipoproteins present in human aortic
valve lesions (39), but oxidized lipids also have been
shown to upregulate the rate of calcium nodule formation
in valvular cells in vitro (40). Several potential mecha-
FIG. 2. Rates of incident AVC by number of MetS components as
defined by ATP III criteria (A) or IDF criteria (B). DM, diabetes.
TABLE 2
Logistic regression models for the risk of incident AVC (among
those free of AVC at baseline) and diabetes, MetS (by ATP III
criteria), or neither condition
Neither
condition MetS Diabetes
n 3,022 1,470 631
Unadjusted 1.0 (ref.) 1.84 (1.35–2.53) 2.54 (1.75–2.53)
Adjusted* 1.0 (ref.) 1.73 (1.25–2.38) 2.16 (1.46–3.19)
Adjusted† 1.0 (ref.) 1.67 (1.21–2.31) 2.06 (1.39–3.06)
Data are OR (95% CI). *Adjusted for time between scans, age, sex,
and race/ethnicity. †Adjusted for time between scans, age, sex,
race/ethnicity, scanner type, LDL cholesterol, lipid-lowering medica-
tions, and smoking.
FIG. 3. Adjusted ORs (boxes) and corresponding 95% CIs (bars) for
incident AVC by number of ATP III MetS criteria or diabetes (DM).
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nisms may contribute to the increased risk of incident AVC
seen with metabolic syndrome and diabetes.
These observational findings also are interesting in light
of the recent demonstration that an elevated total-to-HDL
cholesterol ratio is associated with a consistent increase in
relative risk for AVC across all ages in the MESA cohort
(41). Clinical abnormalities of glucose metabolism (which
include impaired fasting glucose, impaired glucose toler-
ance, and type 2 diabetes) are associated with both a
progressive increase triglyceride-rich VLDL cholesterol
and a progressive decrease in HDL cholesterol (8). To-
gether, these changes increase the total-to-HDL choles-
terol ratio (42). Retrospective studies had suggested a
potential benefit of statin therapy (which primarily lowers
LDL levels) in aortic valve disease (43–46). The results of
subsequent, properly controlled clinical trials of atorvasta-
tin (47) or of simvastatin plus ezetimibe (48) have been
convincingly negative despite average therapy-related LDL
reductions of over 50% in both trials. Because the charac-
teristic MetS lipid abnormalities of high triglycerides and
low HDL result in an increase in the total-to-HDL choles-
terol ratio, it is not known whether more specifically
targeting this MetS-associated dyslipidemia might repre-
sent an effective strategy for decreasing the MetS-associ-
ated risks for incident AVC.
Recent studies have implicated the renin-angiotensin
system, which is upregulated in MetS (2) in aortic valve
disease pathogenesis (49–52). Retrospective studies of
ACE inhibitor therapy have been mixed in the general
population of individuals with aortic sclerosis (50) or
aortic stenosis (46). The results of the present study,
however, raise the possibility that renin-angiotensin sys-
tem inhibitor therapy targeted to those with MetS might
prove effective at slowing the rate of development of
CAVD.
The association of progressive increase in plasma glu-
cose with progressive increase in risk for incident AVC
risk raises the possibility that dysglycemia may represent
an additional therapeutic target in this disease, as has been
demonstrated for atherosclerosis (53).
This study has limitations, which include the possibility
of survival bias, because those with clinical cardiovascular
disease were excluded from MESA; limited statistical
power, because the exclusion of those with known cardio-
vascular disease from MESA may have also resulted in the
exclusion of individuals with MetS (1,2) and AVC (16),
thereby limiting our power to show a relationship between
MetS and AVC progression; dichotomization of continuous
measures such as MetS components, which may decrease
available information and result in misclassification of
exposure; and survival bias attributed to participants who
did not attend the follow-up examinations; and given the
relatively short follow-up time, it is possible that AVC may
not have developed between visits or AVC may not have
been captured by CT scans. Nonetheless, MetS is defined
using cut points in clinical practice. It is reassuring that
similar results were found using both ATP III and IDF
MetS criteria. Strengths of this study include use of a large,
well-characterized, population-based cohort and of a
highly reproducible technique for quantifying AVC.
This study formally tests the hypothesis that MetS is
associated with increased risk for the development of
AVC. These findings further underscore the clinical impor-
tance of identifying MetS in populations without clinical
cardiovascular disease and, further, raise the possibility of
screening for the presence of aortic valve disease in those
with MetS. These findings suggest that future studies
targeting the MetS-associated “atherogenic dyslipidemia”
of high triglycerides and low HDL cholesterol as well as
renin-angiotensin system components and/or insulin resis-
tance may identify useful strategies to decrease the devel-
opment of aortic valve disease.
ACKNOWLEDGMENTS
This research was supported by R01-HL071739 and by
contracts N01-HC-95159 through N01-HC-95165 and N01-
HC-95169 from the National Heart, Lung, and Blood Insti-
tute (NHLBI). The NHLBI participated in the design and
conduct of the MESA study.
M.J.B. has received honoraria from and is on the speak-
ers’ bureau of General Electric. K.D.O. has received hon-
oraria from and is on the speakers’ bureaus of
AstraZeneca, Bristol-Myers Squibb, and Merck. No other
potential conflicts of interest relevant to this article were
reported.
Parts of this study were presented in abstract form
during the American Heart Association Scientific Sessions,
New Orleans, Louisiana, 8–12 November 2008.
TABLE 3
Logistic regression models for the risk of incident AVC (among those free of AVC at baseline) for each component of the MetS in
participants free of diabetes
OR (95% CI)
Adjusted* Adjusted† Adjusted‡
Elevated blood pressure 1.37 (0.96–1.95) 1.34 (0.94–1.91) 1.25 (0.87–1.79)
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cholesterol, lipid-lowering medications, and smoking. ‡Adjusted further for components of the MetS.
FIG. 4. Median AVC change by diabetes, MetS, or neither condition.
“Box” plots the median AVC progression score (middle horizontal
lines) in Agatston units/year and corresponding 25th (lower bound of
box) and 75th (upper bound of box) percentile ranges.
R. KATZ AND ASSOCIATES
DIABETES, VOL. 58, APRIL 2009 817
We thank Susan Larsen for assistance in manuscript
preparation and the other investigators, staff, and partici-
pants of the MESA study for their valuable contributions.
REFERENCES
1. Grundy SM, Cleeman I, Daniels SR, Donato KA, Eckel RH, Franklin BA,
Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F:
Diagnosis and management of the metabolic syndrome: an American Heart
Association/National Heart, Lung, and Blood Institute Scientific Statement.
Circulation 112:2735–2752, 2005
2. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet
365:1415–1428, 2005
3. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome
among US adults: findings from the third National Health and Nutrition
Examination Survey. JAMA 287:356–359, 2002
4. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the
diabetes epidemic. Nature 414:782–787, 2001
5. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The
continuing epidemics of obesity and diabetes in the United States. JAMA
286:1195–1200, 2001
6. AradY, Newstein D, Cadet F, Roth M, Guerci AD: Association of multiple
risk factors and insulin resistance with increased prevalence of asymp-
tomatic coronary artery disease by an electron-beam computed tomo-
graphic study. Arterioscler Thromb Vasc Biol 21:2051–2058, 2001
7. Wong ND, Sciammarella MG, Polk D, Gallagher A, Miranda-Peats L,
Whitcomb B, Hachamovitch R, Friedman JD, Hayes S, Berman DS: The
metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by
coronary calcium. J Am Coll Cardiol 41:1547–1553, 2003
8. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR,
Groop L: Cardiovascular morbidity and mortality associated with the
metabolic syndrome. Diabetes Care 24:683–689, 2001
9. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuom-
ilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular
disease mortality in middle-aged men. JAMA 288:2709–2716, 2002
10. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III: Factors of risk
in the development of coronary heart disease—six year follow-up experi-
ence. The Framingham Study. Ann Intern Med 55:33–50, 1961
11. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE,
Kitzman DW, Otto CM: Clinical factors associated with calcific aortic valve
disease. Cardiovascular Health Study. J Am Coll Cardiol 29:630–634, 1997
12. Otto CM, Pearlman AS: Doppler echocardiography in adults with symp-
tomatic aortic stenosis. Diagnostic utility and cost-effectiveness. Arch
Intern Med 148:2553–2560, 1988
13. Carabello BA: Clinical practice. Aortic stenosis. N Engl J Med 346:677–682,
2002
14. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS: Association of
aortic-valve sclerosis with cardiovascular mortality and morbidity in the
elderly. N Engl J Med 341:142–147, 1999
15. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD,
Miyake-Hull CY, Schwaegler RG: Prospective study of asymptomatic
valvular aortic stenosis. Clinical, echocardiographic, and exercise predic-
tors of outcome. Circulation 95:2262–2270, 1997
16. Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM, Probstfield JL,
Bertoni AG, Budoff MJ, O’Brien KD: Features of the metabolic syndrome
and diabetes mellitus as predictors of aortic valve calcification in the
Multi-Ethnic Study of Atherosclerosis. Circulation 113:2113–2119, 2006
17. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP,
Arsenault M, Couet J, Pibarot P: Metabolic syndrome negatively influences
disease progression and prognosis in aortic stenosis. J Am Coll Cardiol
47:2229–2236, 2006
18. Briand M, Pibarot P, Despres JP, Voisine P, Dumesnil JG, Dagenais F,
Mathieu P: Metabolic syndrome is associated with faster degeneration of
bioprosthetic valves. Circulation 114:I512–I517, 2006
19. Bild DE, Bluemke DA, Burke GL, Detrano R, ez Roux AV, Folsom AR,
Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson C, O’Leary D, Saad
MF, Shea S, Szklo M, Tracy RP: Multi-Ethnic Study of Atherosclerosis:
objectives and design. Am J Epidemiol 156:871–881, 2002
20. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration
of low-density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem 18:499–502, 1972
21. Executive Summary of the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA 285:2486–2497, 2001
22. Budoff MJ, Mao S, Takasu J, Shavelle DM, Zhao XQ, O’Brien KD: Repro-
ducibility of electron-beam CT measures of aortic valve calcification. Acad
Radiol 9:1122–1127, 2002
23. Budoff MJ, Takasu J, Katz R, Mao S, Shavelle DM, O’Brien KD, Blumenthal
RS, Carr J, Kronmal R: Reproducibility of CT measurements of aortic valve
calcification, mitral annulus calcification, and aortic wall calcification in
the Multi-Ethnic Study of Atherosclerosis. Acad Radiol 13:166–172, 2006
24. Budoff MJ, Katz R, Wong ND, Nasir K, Mao SS, Takasu J, Kronmal R,
Detrano RC, Shavelle DM, Blumenthal RS, O’Brien KD, Carr JJ: Effect of
scanner type on the reproducibility of extracoronary measures of calcifi-
cation: the Multi-Ethnic Study of Atherosclerosis. Acad Radiol 14:1043–
1049, 2007
25. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr,
Detrano R: Quantification of coronary artery calcium using ultrafast
computed tomography. J Am Coll Cardiol 15:827–832, 1990
26. Martin RD: Robust Statistics With the S-Plus Robust Library and Finan-
cial Applications. New York: Insightful; 2002
27. Venables WN, Ripley BD: Modern Applied Statistics With S-Plus. New
York: Springer; 1999:167–176
28. Boon A, Cheriex E, Lodder J, Kessels F: Cardiac valve calcification:
characteristics of patients with calcification of the mitral annulus or aortic
valve. Heart 78:472–474, 1997
29. Aronow WS, Schwartz KS, Koenigsberg M: Correlation of serum lipids,
calcium, and phosphorus, diabetes mellitus and history of systemic
hypertension with presence or absence of calcified or thickened aortic
cusps or root in elderly patients. Am J Cardiol 59:998–999, 1987
30. Aronow WS, Ahn C, Kronzon I, Goldman ME: Association of coronary risk
factors and use of statins with progression of mild valvular aortic stenosis
in older persons. Am J Cardiol 88:693–695, 2001
31. Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin JL, Hofmann SM,
Vlassara H, Shi Y: Diabetes-induced oxidative stress and low-grade inflam-
mation in porcine coronary arteries. Circulation 108:472–478, 2003
32. Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA: MSX2
promotes osteogenesis and suppresses adipogenic differentiation of mul-
tipotent mesenchymal progenitors. J Biol Chem 278:45969–45977, 2003
33. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL: Bone
morphogenetic protein expression in human atherosclerotic lesions.
J Clin Invest 91:1800–1809, 1993
34. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL:
TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular
cells to calcify. J Clin Invest 93:2106–2113, 1994
35. Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan
FS: Bone formation and inflammation in cardiac valves. Circulation
103:1522–1528, 2001
36. Wozney JM, Rosen V: Bone morphogenetic protein and bone morphoge-
netic protein gene family in bone formation and repair. Clin Orthop Relat
Res 346:26–37, 1998
37. Baynes JW, Thorpe SR: Glycoxidation and lipoxidation in atherogenesis.
Free Radic Biol Med 28:1708–1716, 2000
38. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW: A
hydroxyl radical-like species oxidizes cynomolgus monkey artery wall
proteins in early diabetic vascular disease. J Clin Invest 107:853–860, 2001
39. Olsson M, Thyberg J, Nilsson J: Presence of oxidized low density lipopro-
tein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol
19:1218–1222, 1999
40. Mohler ER III, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L,
Gannon FH: Identification and characterization of calcifying valve cells
from human and canine aortic valves. J Heart Valve Dis 8:254–260, 1999
41. Owens DS, Katz R, Johnson E, Shavelle DM, Probstfield JL, Takasu J,
Crouse JR, Carr JJ, Kronmal R, Budoff MJ, O’Brien KD: Interaction of age
with lipoproteins as predictors of aortic valve calcification in the Multi-
Ethnic Study of Atherosclerosis. Arch Intern Med 168:1200–1207, 2008
42. Tannock LR, O’Brien KD, Knopp RH, Retzlaff B, Fish B, Wener MH, Kahn
SE, Chait A: Cholesterol feeding increases C-reactive protein and serum
amyloid A levels in lean insulin-sensitive subjects. Circulation 111:3058–
3062, 2005
43. Novaro GM, Tiong Y, Pearce GL, Lauer MS, Sprecher DL, Griffin BP: Effect
of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progres-
sion of calcific aortic stenosis. Circulation 104:2205–2209, 2001
44. Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG,
Achenbach S: Progression of aortic valve calcification: association with
coronary atherosclerosis and cardiovascular risk factors. Circulation
104:1927–1932, 2001
45. Shavelle DM, Takasu J, Budoff MJ, Mao S, O’Brien KD: HMG CoA
reductase inhibitor (statin) and aortic valve calcium. Lancet 359:1125–
1126, 2002
46. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M,
Binder T, Maurer G, Baumgartner H: Statins but not angiotensin-convert-
MetS AND INCIDENT AVC
818 DIABETES, VOL. 58, APRIL 2009
ing enzyme inhibitors delay progression of aortic stenosis. Circulation
110:1291–1295, 2004
47. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB,
Boon NA: A randomized trial of intensive lipid-lowering therapy in calcific
aortic stenosis. N Engl J Med 352:2389–2397, 2005
48. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K,
Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber
CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R: Intensive lipid lowering
with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359:1343–
1356, 2008
49. O’Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto
CM, Probstfield JL: Association of angiotensin-converting enzyme with
low-density lipoprotein in aortic valvular lesions and in human plasma.
Circulation 106:2224–2230, 2002
50. O’Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM,
Wu AH, Zhao XQ, Budoff MJ: Angiotensin-converting enzyme inhibitors
and change in aortic valve calcium. Arch Intern Med 165:858–862, 2005
51. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J,
Turto H, Kupari M, Kovanen PT: Induction of local angiotensin II-
producing systems in stenotic aortic valves. J Am Coll Cardiol 44:1859–
1866, 2004
52. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T,
Hanafusa T: Angiotensin receptor-1 blocker inhibits atherosclerotic
changes and endothelial disruption of the aortic valve in hypercholester-
olemic rabbits. J Am Coll Cardiol 49:1482–1489, 2007
53. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up
of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–
1589, 2008
R. KATZ AND ASSOCIATES
DIABETES, VOL. 58, APRIL 2009 819
